The Charing Cross Hospital experience with temozolomide in patients with gliomas

European Journal of Cancer Part A

Volumn 32, Issue 13, 1996, Pages 2236-2241

  Newlands, E S ^a   O'Reilly, S M ^a   Glaser, M G ^a   Bower, M ^a   Evans, H ^a   Brock, C ^a   Brampton, M H ^a   Colquhoun, I ^a   Lewis, P ^a   Rice Edwards, J M ^a   Illingworth, R D ^a   Richards, P G ^a  

^a CHARING CROSS HOSPITAL   (United Kingdom)

Author keywords

Alkylating agents; Astrocytomas; Chemotherapy; Gliomas; Temozolomide

Indexed keywords

TEMOZOLOMIDE;

ADULT; AGED; ANEMIA; ARTICLE; BONE MARROW SUPPRESSION; CANCER RECURRENCE; CANCER REGRESSION; CANCER SURVIVAL; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; DRUG EFFICACY; FEMALE; GLIOMA; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; THROMBOCYTOPENIA;

ADULT; AGED; ANTINEOPLASTIC AGENTS, ALKYLATING; BRAIN NEOPLASMS; COMBINED MODALITY THERAPY; DACARBAZINE; FEMALE; GLIOMA; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; SURVIVAL RATE; TOMOGRAPHY, X-RAY COMPUTED;

EID: 0030449301     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(96)00258-4     Document Type: Article

References (40)

1. 1. Walker ME, Alexander E, Hunt WE, et al. Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas: a co-operative clinical trial. J Neurosurg 1978, 49, 333-343.
2. 2. Stewart DJ. The role of chemotherapy in the treatment of gliomas in adults. Cancer Treat Rev 1989, 16, 129-160.
3. 3. Fine HA, Dear KBG, Loeffler JS, et al. Meta-analysis of radiation therapy with and without adjuvant chemotherapy for malignant gliomas in adults. Cancer 1993, 71, 2585-2587.
4. 4. Levin VA, Edwards MS, Wright DC, et al. Modified procarbazine, CCNU, and vincristine (PCV 3) combination chemotherapy, in the treatment of malignant brain tumors. Cancer Treat Rep 1980, 64, 237-241.
5. 5. Sandberg-Wollheim M, Malmström P, Lars-Göran S, et al. A randomized study of chemotherapy with procarbazine, vincristine and lomustine with and without radiation therapy for astrocytoma grades 3 and/or 4. Cancer 1991, 68, 22-29.
6. 6. Rodriguez LA, Levin VA. Does chemotherapy benefit the patient with a central nervous system glioma? Oncology 1987, 1, 29-36.
7. 7. Georges P, Przedborski S, Brotchi J, et al. Effect of HECNU in malignant supratentorial gliomas: a phase II study. J Neuro-oncol 1988, 6, 211-219.
8. 8. MacDonald DR, Cascino TL, Schold SC, et al. Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 1990, 8, 1277-1280.
9. 9. Watling CJ, Lee DH, Macdonald DR, et al. Corticosteroid-induced magnetic resonance imaging changes in patients with recurrent malignant glioma. J Clin Oncol 1994, 12, 1886-1889.
10. 10. Report of the Medical Research Council Brain Tumour Working Party. Prognostic factors for high-grade malignant glioma: development of a prognostic index. J Neuro-oncology 9, 47-55.
11. 11. Ganju V, Jenkins RB, O'Fallon JR, et al. Prognostic factors in gliomas. A multivariate analysis of clinical, pathologic, flow cytometric, cytogenetic and molecular markers. Cancer 1994, 74, 920-927.
12. 12. Rajan B, Ross G, Lim CC, et al. Survival in patients with recurrent glioma as a measure of treatment efficacy: prognostic factors following nitrosourea chemotherapy. Eur J Cancer 1994, 30A, 1809-1815.
13. 13. Cavenee WK. Accumulation of genetic defects during astrocytoma progression. Cancer 1992, 70, 1788-1793.
14. 14. Stevens MFG, Hickman JA, Langden SP, et al. Antitumour activity and pharmacokinetics in mice of 8-carbomyl-3-methyl-imidazo(5,1-d)-1,2,3,5-tetrazin-4(3H)-one (CCRG 81045; M&B 39831), a novel drug with potential as an alternative to dacarbazine. Cancer Res 1987, 47, 5846-5852.
15. 15. Newlands ES, Blackledge GRP, Slack JA. Phase I trial of temozolomide (CCRG 81045; M&B 39831; NSC 362856). Br J Cancer 1992, 65, 287-291.
16. 16. O'Reilly SM, Newlands ES, Glaser MG, et al. Temozolomide: a new oral cytotoxic chemotherapeutic agent with promising activity against primary brain tumours. Eur J Cancer 1993, 29A, 940-942.
17. 17. Bleehen NM, Newlands ES, Lee SM, et al. Cancer Research Campaign Phase II trial of temozolomide in metastatic melanoma. J Clin Oncol 1995, 13, 910-913.
18. 18. Woll PJ, Crowther D, Johnson PWM, et al. Phase II trial of temozolomide in low grade non-Hodgkin's lymphoma. Br J Cancer 1995, 72, 183-184.
19. 19. Daumas-Duport C, Scheithauer B, O'Fallon J, Kelly P. Grading of astrocytomas, a simple and reproducible method. Cancer 1988, 62, 2152-2165.
20. 20. Bleehen NM, Freedman LS, Stenning SP. A randomised study of CCNU with and without benznidazole in the treatment of recurrent grades 3 and 4 astrocytoma. Int J Radiat Oncol Biol Phys 1989, 16, 1077-1081.
21. 21. Bower M, Newlands ES, Bleehen NM, Brampton MH, et al. Cancer Research Campaign Phase II trial of temozolomide in high grade glioma. Manuscript in preparation.
22. 22. Hjermstad MJ, Fossa SD, Bjordal K, et al. Test/retest study of the European Organization for Research and Treatment of Cancer Core Quality-of-Life Questionnaire. J Clin Oncol 1995, 13, 1249-1254.
23. 23. Aaronson N, Osoba D, Yung W, et al. Health-related quality of life (HQL) measurement in patients with brain cancer. Proc Am Soc Clin Oncol 1995, 14, 280 (abstract).
24. 24. Osoba D, Aaronson NK, Muller M, et al. The development and psychometric validation of a brain cancer quality-of-life questionnaire for use in combination with general cancer-specific questionnaires. Qual Life Res, in press.
25. 25. O'Reilly SM, Harte RJA, Newlands ES, et al. Early changes in tumor glucose metabolism may predict and quantify response of gliomas to chemotherapy: a phase II study using temozolomide. Proc Am Soc Clin Oncol 1995, 14, 1635 (abstract).
26. 26. Hajnal JV, Saeed N, Soar EJ, et al. A registration and interpolation procedure for subvoxel matching of serially acquired magnetic resonance images. J Comput Assist Tomogr 1995, 19, 289-296.
27. 6-methylguanine-DNA-methyltransferase activity and resistance of human cells to the cytotoxic and mutagenic effect of N-methyl-N-nitrosoguanidine. Carcinogenesis (London) 1984, 5, 1641-1647.
28. 28. Catapano CV, Broggini M, Erba E, et al. In vitro and in vivo methazolastone-induced DNA damage and repair in L1210 leukemia sensitive and resistant to chloroethylnitrosoureas. Cancer Res 1987, 47, 4884-4889.
29. 29. Pegg AE. Alkylation and subsequent repair of DNA after exposure to dimethylnitrosamine and related carcinogens. Rev Biochem Toxicol 1983, 5, 83-133.
30. 6-benzylguanine analogues on sensitivity of human tumour cells to the cytotoxic effects of alkylating agents. Cancer Res 1991, 51, 3367-3372.
31. 6-benzylguanine on the sensitivity of human tumour xenografts to 1,3-bis(2-chloroethyl)-1-nitrosourea and on DNA interstrand cross-link formation. Cancer Res 1992, 52, 1171-1175.
32. 32. Friedman HS, Dolan ME, Moschel RC, et al. Enhancement of nitrosourea activity in medulloblastoma and glioblastoma multiforme. J Natl Cancer Inst 1992, 84, 1926-1931.
33. 6-methylguanine and temozolomide can reverse the resistance to chloroethylnitrosoureas of a mouse L1210 leukemia. Anticancer Res 1991, 11, 115-122.
34. 6-alkylguanine - DNA alkyltransferase activity and sensitivity of human tumor cells and xenografts to 1,3-bis(2-chloroethyl)-1-nitrosourea. Cancer Chemother Pharmacol 1993, 32, 59-63.
35. 6-alkylguanine - DNA alkyltransferase correlates with potentiation of temozolomide and CCNU toxicity in human tumour cells. Br J Cancer 1993, 67, 1299-1302.
36. 6-benzylguanine with or without streptozotocin enhances 1,3-bis(2-chloroethyl)-1-nitrosourea sensitivity in vitro. Cancer Res 1993, 53, 4281-4286.
37. 6-alkylguanine - DNA alkyltransferase in human peripheral blood mononuclear cells by temozolomide. Br J Cancer 1994, 53, 452-456.
38. 6-benzylguanine: a comparative study in vitro. Br J Cancer, in press.
39. 6-benzylguanine enhances temozolomide and 1,3-bis(2-chloroethyl)-nitrosourea activity in a Mer human glioma xenograft. Br J Cancer, in press.
40. 40. Friedman HS, Dolan ME, Pegg AE, et al. Activity of temozolomide in the treatment of central nervous system tumor xenografts. Cancer Res 1995, 55, 2853-2857.